Tag: Astellas Pharma Inc

FDA approves Medivation prostate cancer drug

Your Health Matters

(Reuters) – A novel prostate cancer drug developed by Medivation Inc and Astellas Pharma Inc has been approved by the U.S. Food and Drug Administration for men whose cancer has spread despite treatment with hormone therapy and chemotherapy, the agency said on Friday. Approval of the pill, to be sold under the brand name Xtandi, comes three months ahead of the agency’s late-November decision deadline and sent shares of Medivation up 7.6 percent. Wall Street analysts, on average, have forecast Medivation’s sales of the drug at $1.2 billion by 2017, according to Thomson Pharma. …

, , ,

Drugmaker Medivation posts loss as expenses jump

Your Health Matters

(Reuters) – Drugmaker Medivation Inc returned to recording a quarterly loss after a rare first-quarter profit as expenses rose, sending its shares down 3 percent after market. April-June net loss narrowed to $5.5 million, or 15 cents per share, from $9.5 million, or 27 cents per share, a year earlier. Revenue, which Medivation generates mostly through collaborations with Astellas Pharma Inc, more than doubled to $42.9 million, boosted by $35.6 million of deferred revenue from ending a drug development deal with Pfizer Inc. …

, , ,